Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 15;14:5727. doi: 10.1038/s41467-023-41282-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Schema of TNBC orthotopic xenograft model (SUM159) infused with CAR T. b Tumor volumes (untreated n = 5, CAR T n = 20, DSF/Cu+IR + CAR T n = 20) measured every 4 days. c Comparison of tumor volumes in mice treated with the same patient’s PBMC-derived CAR T vs. DSF/Cu+IR + CAR T on days 0, 4, 8, 12 post-CAR T infusion (CAR T n = 20, DSF/Cu+IR + CAR T n = 20). d Kaplan–Meier survival curve of mice (untreated n = 5, CAR T n = 20, DSF/Cu+IR + CAR T n = 20). e Frequency of B7-H3 CAR T cells in peripheral blood 9 days post-CAR T injection (CAR T n = 20, DSF/Cu+IR + CAR T n = 20). f Early memory B7-H3 CAR T, defined by CD45RA and CD62L on CD3⁺ in peripheral blood collected from mice 10 days after the CAR T infusion. Percentages of T_SCM/T_CM/T_EM/T_EFF CAR T are shown (n = 9). g Frequency of B7-H3 CAR T expressing markers associated with T-cell exhaustion (CD3⁺PD-1⁺, CD3⁺LAG3⁺, or CD3⁺TIM3⁺ in peripheral blood collected from treated mice 9 days post CAR T injection (n = 9/group). h Comparison of percentages of circulating T_SCM and T_CM of B7-H3 CAR T in tumor-bearing mice with complete response (CR) vs. partial response (PR) 24 days post CAR T infusion (CR: n = 12, PR: n = 8). i Reverse correlation of percentages of early/effector-memory NRPB7-H3 CAR T with tumor burden (high tumor volume group n = 12; low tumor volume group n = 8). j Schema of TNBC-PDX mouse model. k, Tumor volumes (vehicle n = 6; the other two groups n = 7) of each group. l Frequency of B7-H3 CAR T cells (CD3⁺CD45⁺) in the blood of mice collected weekly (n = 7/group). m Kaplan–Meier survival curve of mice (vehicle n = 6; the other two groups n = 7). Data “n” represents biological replicates. Statistical comparisons were performed using a two-tailed unpaired t-test (c, h, i), log-rank test (d, m), two-tailed paired t-test (e, f, g), and two-way ANOVA with Tukey’s multiple comparisons test (k, l). P-values are shown and error bars indicate mean ± SD. Source data are provided as a Source Data file.